Table of Content
1.INTRODUCTION
1.1OBJECTIVES OF THE STUDY
1.2MARKET DEFINITION
1.3OVERVIEW OF GLOBAL SMART INSULIN PEN MARKET
1.4CURRENCY AND PRICING
1.5LIMITATION
1.6MARKETS COVERED
2.MARKET
2.1KEY TAKEAWAYS
2.2ARRIVING AT THE GLOBAL SMART INSULIN PEN MARKET SIZE
2.2.1VENDOR POSITIONING GRID
2.2.2TECHNOLOGY LIFE LINE CURVE
2.2.3TRIPOD DATA VALIDATION MODEL
2.2.4MARKET GUIDE
2.2.5MULTIVARIATE MODELLING
2.2.6TOP TO BOTTOM ANALYSIS
2.2.7CHALLENGE MATRIX
2.2.8APPLICATION COVERAGE GRID
2.2.9STANDARDS OF MEASUREMENT
2.2.10VENDOR SHARE ANALYSIS
2.2.11EPIDEMIOLOGY
2.2.12DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13DATA POINTS FROM KEY SECONDARY DATABASES
2.3GLOBAL SMART INSULIN PEN MARKET: RESEARCH SNAPSHOT
2.4ASSUMPTIONS
3.MARKET OVERVIEW
3.1DRIVERS
3.2RESTRAINTS
3.3OPPORTUNITIES
3.4CHALLENGES
4.EXECUTIVE SUMMARY
5.PREMIUM INSIGHTS
6.EPIDEMIOLOGY
6.1INCIDENCE OF ALL BY GENDER
6.2TREATMENT RATE
6.3MORTALITY RATE
6.4DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5PATEINT TREATMENT SUCCESS RATES
7.INDUSTRY INSIGHTS
7.1PATENT ANALYSIS
7.2DRUG TREATMENT RATE BY MATURED MARKETS
7.3DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
7.4PATIENT FLOW DIAGRAM
7.5KEY PRICING STRATEGIES
7.6KEY PATIENT ENROLLMENT STRATEGIES
7.7INTERVIEWS WITH CARDIOLOGIST
7.8OTHER KOL SNAPSHOTS
8.REGULATORY SCENARIO
9.PIPELINE ANALYSIS
9.1PHASE III CANDIDATES
9.2PHASE II CANDIDATES
9.3PHASE I CANDIDATES
9.4OTHERS (PRE-CLINICAL AND RESEARCH)
10.GLOBAL SMART INSULIN PEN MARKET, BY PRODUCT TYPE
10.1OVERVIEW
10.2INTEGRATED SMART INSULIN PENS
10.3ADAPTORS FOR CONVETIONAL PENS
10.3.1REUSABLE
10.3.2DISPOSABLE
10.4OTHERS
11.GLOBAL SMART INSULIN PEN MARKET, BY USABILITY
11.1OVERVIEW
11.2PREFILLED
11.3REUSABLE
12.GLOBAL SMART INSULIN PEN MARKET, BY TYPE
12.1OVERVIEW
12.2FIRST GENERATION PENS
12.3SECOND GENERATION PENS
13.GLOBAL SMART INSULIN PEN MARKET, BY CONNECTIVITY
13.1OVERVIEW
13.2BLUETOOTH
13.2.1BY COMPATIBILITY
13.2.1.1.ANDROID
13.2.1.2.IOS
13.2.2BY BRAND
13.2.2.1.INPEN
13.2.2.2.VIGIPEN
13.2.2.3.ESYSTA
13.2.2.4.YPSOMATE SMARTPILOT
13.2.2.5.OTHERS
13.3USB
13.3.1BY COMPATIBILITY
13.3.1.1.ANDROID
13.3.1.2.IOS
13.3.2BY BRAND
13.3.2.1.PENDIQ 2.0
13.3.2.2.OTHERS
13.4NFC
13.4.1BY COMPATIBILITY
13.4.1.1.ANDROID
13.4.1.2.IOS
13.4.2BY BRAND
13.4.2.1.NOVOPEN 6
13.4.2.2.NOVOPEN ECHO
13.4.2.3.OTHERS
13.5OTHERS
14.GLOBAL SMART INSULIN PEN MARKET, BY DISEASE TYPE
14.1OVERVIEW
14.2TYPE 1 DIABETES
14.2.1PREFILLED
14.2.2REUSABLE
14.3TYPE 2 DIABETES
14.3.1PREFILLED
14.3.2REUSABLE
15.GLOBAL SMART INSULIN PEN MARKET, BY END USER
15.1OVERVIEW
15.2HOSPITAL
15.3SPECIALITY CLINICS
15.4HOME HEALTHCARE
15.5OTHERS
16.GLOBAL SMART INSULIN PEN MARKET, BY DISTRIBUTION CHANNEL
16.1OVERVIEW
16.2HOSPITAL PHARMACY
16.3RETAIL PHARMACY
16.4ONLINE PHARMACY
16.5OTHERS
17.GLOBAL SMART INSULIN PEN MARKET, BY GEOGRAPHY
17.1GLOBAL SMART INSULIN PEN MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.1.1NORTH AMERICA
17.1.1.1.U.S.
17.1.1.2.CANADA
17.1.1.3.MEXICO
17.1.2EUROPE
17.1.2.1.GERMANY
17.1.2.2.FRANCE
17.1.2.3.U.K.
17.1.2.4.HUNGARY
17.1.2.5.LITHUANIA
17.1.2.6.AUSTRIA
17.1.2.7.IRELAND
17.1.2.8.NORWAY
17.1.2.9.POLAND
17.1.2.10.ITALY
17.1.2.11.SPAIN
17.1.2.12.RUSSIA
17.1.2.13.TURKEY
17.1.2.14.NETHERLANDS
17.1.2.15.SWITZERLAND
17.1.2.16.REST OF EUROPE
17.1.3ASIA-PACIFIC
17.1.3.1.JAPAN
17.1.3.2.CHINA
17.1.3.3.SOUTH KOREA
17.1.3.4.INDIA
17.1.3.5.AUSTRALIA
17.1.3.6.SINGAPORE
17.1.3.7.THAILAND
17.1.3.8.MALAYSIA
17.1.3.9.INDONESIA
17.1.3.10.PHILIPPINES
17.1.3.11.VIETNAM
17.1.3.12.REST OF ASIA-PACIFIC
17.1.4SOUTH AMERICA
17.1.4.1.BRAZIL
17.1.4.2.ARGENTINA
17.1.4.3.PERU
17.1.4.4.REST OF SOUTH AMERICA
17.1.5MIDDLE EAST AND AFRICA
17.1.5.1.SOUTH AFRICA
17.1.5.2.SAUDI ARABIA
17.1.5.3.UAE
17.1.5.4.EGYPT
17.1.5.5.KUWAIT
17.1.5.6.ISRAEL
17.1.5.7.REST OF MIDDLE EAST AND AFRICA
17.1.6KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18.GLOBAL SMART INSULIN PEN MARKET, SWOT AND DBMR ANALYSIS
19.GLOBAL SMART INSULIN PEN MARKET, COMPANY LANDSCAPE
19.1COMPANY SHARE ANALYSIS: GLOBAL
19.2COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3COMPANY SHARE ANALYSIS: EUROPE
19.4COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5MERGERS & ACQUISITIONS
19.6NEW PRODUCT DEVELOPMENT & APPROVALS
19.7EXPANSIONS
19.8REGULATORY CHANGES
19.9PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20.GLOBAL SMART INSULIN PEN MARKET, COMPANY PROFILE
20.1PENDIQ
20.1.1COMPANY OVERVIEW
20.1.2REVENUE ANALYSIS
20.1.3GEOGRAPHIC PRESENCE
20.1.4PRODUCT PORTFOLIO
20.1.5RECENT DEVELOPMENTS
20.2NOVO NORDISK
20.2.1COMPANY OVERVIEW
20.2.2REVENUE ANALYSIS
20.2.3GEOGRAPHIC PRESENCE
20.2.4PRODUCT PORTFOLIO
20.2.5RECENT DEVELOPMENTS
20.3MEDTRONIC
20.3.1COMPANY OVERVIEW
20.3.2REVENUE ANALYSIS
20.3.3GEOGRAPHIC PRESENCE
20.3.4PRODUCT PORTFOLIO
20.3.5RECENT DEVELOPMENTS
20.4US MED
20.4.1COMPANY OVERVIEW
20.4.2REVENUE ANALYSIS
20.4.3GEOGRAPHIC PRESENCE
20.4.4PRODUCT PORTFOLIO
20.4.5RECENT DEVELOPMENTS
20.5INSULCLOUD S.L.
20.5.1COMPANY OVERVIEW
20.5.2REVENUE ANALYSIS
20.5.3GEOGRAPHIC PRESENCE
20.5.4PRODUCT PORTFOLIO
20.5.5RECENT DEVELOPMENTS
20.6TIMESULIN (PATIENTS PENDING LTD)
20.6.1COMPANY OVERVIEW
20.6.2REVENUE ANALYSIS
20.6.3GEOGRAPHIC PRESENCE
20.6.4PRODUCT PORTFOLIO
20.6.5RECENT DEVELOPMENTS
20.7EMPERRA GMBH E-HEALTH TECHNOLOGIES
20.7.1COMPANY OVERVIEW
20.7.2REVENUE ANALYSIS
20.7.3GEOGRAPHIC PRESENCE
20.7.4PRODUCT PORTFOLIO
20.7.5RECENT DEVELOPMENTS
20.8YPSOMED
20.8.1COMPANY OVERVIEW
20.8.2REVENUE ANALYSIS
20.8.3GEOGRAPHIC PRESENCE
20.8.4PRODUCT PORTFOLIO
20.8.5RECENT DEVELOPMENTS
20.9BIGFOOT BIOMEDICAL, INC.
20.9.1COMPANY OVERVIEW
20.9.2REVENUE ANALYSIS
20.9.3GEOGRAPHIC PRESENCE
20.9.4PRODUCT PORTFOLIO
20.9.5RECENT DEVELOPMENTS
20.10BIOCORP
20.10.1COMPANY OVERVIEW
20.10.2REVENUE ANALYSIS
20.10.3GEOGRAPHIC PRESENCE
20.10.4PRODUCT PORTFOLIO
20.10.5RECENT DEVELOPMENTS
20.11JIANGSU DELFU MEDICAL DEVICE CO.,LTD
20.11.1COMPANY OVERVIEW
20.11.2REVENUE ANALYSIS
20.11.3GEOGRAPHIC PRESENCE
20.11.4PRODUCT PORTFOLIO
20.11.5RECENT DEVELOPMENTS
20.12ELI LILLY AND COMPANY
20.12.1COMPANY OVERVIEW
20.12.2REVENUE ANALYSIS
20.12.3GEOGRAPHIC PRESENCE
20.12.4PRODUCT PORTFOLIO
20.12.5RECENT DEVELOPMENTS
20.13BIOCORP
20.13.1COMPANY OVERVIEW
20.13.2REVENUE ANALYSIS
20.13.3GEOGRAPHIC PRESENCE
20.13.4PRODUCT PORTFOLIO
20.13.5RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21.RELATED REPORTS
22.CONCLUSION
23.QUESTIONNAIRE
24.ABOUT DATA BRIDGE MARKET RESEARCH
